Patients receiving medical cannabis through statutory health insurance face a potential turning point. At the end of March 2026, the Finance Commission for Health released its first major reform report — and one of 66 recommendations directly impacts cannabis patients: flower will no longer be covered by statutory health insurance. What was once standard practice could become an expensive private matter for many patients.
📑 Inhaltsverzeichnis
What the Health Finance Commission Recommends
The Finance Commission, established to stabilize GKV finances, clearly stated in Recommendation 42: cannabis flower should be removed from the statutory health insurance benefit catalog. Standardized extracts and approved finished pharmaceuticals — such as dronabinol or nabilone — would continue to be covered. Flower, however, would become an out-of-pocket expense: still available at pharmacies, but at patient cost.
The Commission’s rationale sounds technical but carries real consequences: the evidence base for the therapeutic benefit of flower is less robust than for finished pharmaceuticals. Additionally, uniform and consistent dosing is scarcely possible — an argument pharmacists and patients have heard for years from the medical community. The savings would be substantial: approximately 130 million euros in 2027, rising to 180 million euros by 2030, based on current GKV spending on flower-based products.
Why Flower Is the Target
Medical cannabis in the form of dried flower remains the most frequently prescribed product in Germany’s medicinal cannabis market. The range of prescribed varieties has grown significantly over the past two years — more than 720 different cannabis strains were available in pharmacies by the end of 2025, substantially more than a year prior. That this segment is now targeted by cost-cutting measures is no accident: flower accounts for a large portion of costs while being the least standardized delivery form.
For critics of the proposal, however, this is not an argument against flower but against undifferentiated cost-cutting. Extracts cannot simply substitute for every patient. Different absorption rates, effect profiles, and individual tolerances make flower medically sound for certain patient groups — not as a lifestyle choice, but as a therapeutic necessity.
Pharmacists and Industry Groups Sound Alarm
The response from the pharmacy sector was sharp. The Association of Cannabis-Supplying Pharmacies (VCA) immediately and clearly opposed the Commission’s recommendation. VCA Managing Director Christiane Neubaur stated bluntly: it was „unconscionable to take this away from people.“ The association sees no systemic savings effect in the proposal, only direct hardship for seriously ill patients dependent on this therapy.
The Federal Association of Pharmaceutical Cannabis Industry (BPC) also criticized the GKV cost-cutting plans. Both associations argue that removal creates not only a financial barrier but risks patients discontinuing therapy or turning to uncontrolled sources — undermining the very goal of the Medical Cannabis Act, which is to ensure safe and controlled supply.
What This Means for Patients
Approximately one million patients in Germany now use medical cannabis, many with chronic pain disorders, sleep disturbances, PTSD, or spasticity from neurological conditions. For some of these patients, loss of GKV coverage for flower would be a significant setback. Monthly costs for cannabis-based therapies vary widely depending on prescription quantity and strain — but can easily reach several hundred euros.
The Finance Commission’s recommendation is not yet law. It is a recommendation, not a binding decision. Medical cannabis reform has been advancing on multiple fronts for months: telehealth restrictions, shipping bans for flower, and now potential GKV exclusion. Patients and physicians are urged to engage in the political process — before recommendations become legislation.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
